Papić Eliša, Rački Valentino, Hero Mario, Tomić Zoran, Starčević-Čižmarević Nada, Kovanda Anja, Kapović Miljenko, Hauser Goran, Peterlin Borut, Vuletić Vladimira
Department of Neurology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
Clinic of Neurology, Clinical Hospital Center Rijeka, Rijeka, Croatia.
Front Aging Neurosci. 2022 Dec 8;14:1020172. doi: 10.3389/fnagi.2022.1020172. eCollection 2022.
Parkinson's disease (PD) is neurodegenerative disease with a multifactorial etiopathogenesis with accumulating evidence identifying microbiota as a potential factor in the earliest, prodromal phases of the disease. Previous research has already shown a significant difference between gut microbiota composition in PD patients as opposed to healthy controls, with a growing number of studies correlating gut microbiota changes with the clinical presentation of the disease in later stages, through various motor and non-motor symptoms. Our aim in this systematic review is to compose and assess current knowledge in the field and determine if the findings could influence future clinical practice as well as therapy in PD.
We have conducted a systematic review according to PRISMA guidelines through MEDLINE and Embase databases, with studies being selected for inclusion via a set inclusion and exclusion criteria.
20 studies were included in this systematic review according to the selected inclusion and exclusion criteria. The search yielded 18 case control studies, 1 case study, and 1 prospective case study with no controls. The total number of PD patients encompassed in the studies cited in this review is 1,511.
The link between gut microbiota and neurodegeneration is a complex one and it depends on various factors. The relative abundance of various microbiota taxa in the gut has been consistently shown to have a correlation with motor and non-motor symptom severity. The answer could lie in the products of gut microbiota metabolism which have also been linked to PD. Further research is thus warranted in the field, with a focus on the metabolic function of gut microbiota in relation to motor and non-motor symptoms.
帕金森病（PD）是一种神经退行性疾病，其病因多因素，越来越多的证据表明微生物群是该疾病最早的前驱期的一个潜在因素。先前的研究已经表明，PD患者的肠道微生物群组成与健康对照者存在显著差异，越来越多的研究通过各种运动和非运动症状，将肠道微生物群的变化与疾病后期的临床表现联系起来。本系统评价的目的是整理和评估该领域的现有知识，并确定这些发现是否会影响PD的未来临床实践和治疗。
我们根据PRISMA指南，通过MEDLINE和Embase数据库进行了系统评价，通过一套既定的纳入和排除标准选择纳入研究。
根据选定的纳入和排除标准，本系统评价纳入了20项研究。检索得到18项病例对照研究、1项病例研究和1项无对照的前瞻性病例研究。本综述引用的研究中涵盖的PD患者总数为1511例。
肠道微生物群与神经退行性变之间的联系很复杂，它取决于多种因素。肠道中各种微生物类群的相对丰度一直被证明与运动和非运动症状的严重程度相关。答案可能在于肠道微生物群代谢产物，这些产物也与PD有关。因此，该领域有必要进一步开展研究，重点关注肠道微生物群与运动和非运动症状相关的代谢功能。
